Results 11 to 20 of about 12,785,139 (351)

The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells

open access: yesHaematologica, 2017
The development of inhibitory antibodies to therapeutic factor VIII is the major complication of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti-factor VIII immune response is factor VIII interaction with ...
Bagirath Gangadharan   +6 more
doaj   +2 more sources

von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII

open access: yesHaematologica, 2016
It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of recombinant von Willebrand factor with immature monocyte-derived ...
Nicoletta Sorvillo   +8 more
doaj   +2 more sources

Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A

open access: yesHaematologica, 2015
A large fraction of factor VIII in blood originates from liver sinusoidal endothelial cells although extrahepatic sources also contribute to plasma factor VIII levels.
Diego Zanolini   +12 more
doaj   +2 more sources

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity

open access: yesHaematologica, 2015
The rising incidence of neutralizing antibodies (inhibitors) against therapeutic factor VIII prompted the conduct of studies to answer the question as to whether this rise is related to the introduction of recombinant factor VIII products.
Johannes Oldenburg   +2 more
doaj   +2 more sources

Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients

open access: yesHaematologica, 2013
Since 1981, the number of factor VIII units to infuse into patients with hemophilia A in order to achieve adequate circulating factor VIII levels has been calculated using the formula: [body weight(kg)×desired factor VIII increase(%)]/2, assuming a ...
Séverine Henrard   +2 more
doaj   +2 more sources

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

open access: yesNature Communications, 2013
It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within ...
Timothy C Nichols   +2 more
exaly   +2 more sources

AAV5–Factor VIII Gene Transfer in Severe Hemophilia A

open access: yesNew England Journal of Medicine, 2017
Savita Rangarajan   +2 more
exaly   +2 more sources

A critical appraisal of one‐stage and chromogenic assays of factor VIII activity

open access: yesJournal of Thrombosis and Haemostasis, 2016
F. Peyvandi, J. Oldenburg, K. Friedman
exaly   +2 more sources

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.

open access: yesNew England Journal of Medicine, 2021
BACKGROUND The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector dose.
Lindsey A. George   +18 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy